COAG · Hemab Therapeutics Holdings, Inc. · Executive Compensation
$38.71
-0.45 (-1.14%)
At close · Nov 19
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$1.83B
Shares
46.73M
Volume · Nov 19
43.99K
Avg daily vol (3M)
496.12K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Keli Walbert | member of the Board | Appointed | 2026-09-24 |
|
Laura Tadvalkar, Ph.D.
“Dr. Tadvalkar’s resignation from the Board was not related to any disagreement with the Company on any matter relating to its operations, policies or practices.”
|
member of the Company's board of directors | Resigned | 2026-05-11 |
Leadership
- Keli Walbert Board Member
Key facts
CIK
2114044
CUSIP
423494103
13F (30d)
89 filings
88 filers
Visit website
Investor relations